AVT33

About Alvotech

Alvotech is a mission-driven, publicly traded biosimilar developer with a fully integrated platform that spans the entire value chain from cell line development to commercial fill-and-finish. This vertical integration provides strategic control over timelines, quality, and cost, enabling the company to bring affordable alternatives to high-cost biologic medicines to market efficiently. Its primary achievement is the approval and launch of its high-concentration adalimumab biosimilar (AVT02, referencing Humira) in key markets including the U.S., EU, and Japan, establishing a commercial foundation. The company's strategy is to leverage its platform to build a broad and deep pipeline targeting over a dozen blockbuster biologics, forming strategic commercialization partnerships to maximize global reach.

Therapeutic Areas

Other Oncology (Various Cancers) Drugs